Clario cardiac safety

Monitor every heartbeat with precision and ensure safety
Cardiac safety issues are a key driver in drug development delays and abandonment.

Cardiac safety concerns are among the leading reasons that promising drugs are delayed or abandoned in development and not brought to market. Important safety issues, coupled with a complex regulatory landscape, mean you need expert guidance to minimize risks and bring clinical treatments to market faster—and with confidence.

Increase patient safety with centralized solutions

Be confident in your data with centralized solutions. Our dedicated team focuses on studying ECGs, which means fewer queries and no missing data. With all your data in one place, you can save time and navigate the unexpected. You are not limited to a “one-size-fits-all” approach when you partner with us on cardiac safety. Instead, empower your studies with rapid configuration and analysis, real-time trial visibility and additional endpoints integrated into Clario’s EXPERT®, our proprietary technology platform.

Empower your studies with standard assessments, high-quality data and centralized monitoring

- QT interval and t-wave morphology
- Ambulatory blood
- ePRO
- EDC
- CTMS
- IVR
- Images
- Precision motion
- Medical devices
- Labs

Cardiac safety consulting services

Clario cardiac safety
Centralized data analysis

Standard assessments

High-quality data

Centralized monitoring

Minimize risk
Have confidence in your cardiac safety strategy

Access enhanced cardiac safety services that leverage the capabilities of iCardiac Technologies and Biomedical Systems, both of which were acquired by Clario in 2017. Our team of scientists and clinicians can select the best strategy for analyzing cardiac safety and determine the best devices to collect high-quality data for your trial. Having completed over 19,000 trials across all clinical phases and therapeutic areas, Clario has invested in a trial experience that simplifies process and engagement with sponsors, sites, patients and CROs, improving speed and agility.

Standardized and centralized cardiac safety assessments in early-phase trials.
When every millisecond of precision counts, confidently navigate cardiac safety assessments in your early-phase trial to support protocol compliance, improve data quality, reduce investigator workload and shorten time-to-market. Minimize risk and make smart decisions with our EPQT solution.

Have confidence in late-phase study results with centralized data. Relying on site-managed ECG devices introduces variability and can lead to poor patient inclusion and exclusion criteria and enrollment decisions, posing potential danger to study subjects. Instead, optimize patient enrollment and minimize risk by centralizing all your ECG data in one place with our SafePatient ECG solution.

Ensure high-quality cardiac safety data. Confidently navigate unexpected issues throughout your trial by collaborating with our Phase 1 Center of Excellence and highly-trained and qualified certified and preferred sites. Our team of experts can help determine the best strategy for analyzing cardiac safety and the best devices to collect high-quality data.

Providing cardiac safety services for:
- 13,887 cardiac trials supported
- 580 new drug approvals
- 600+ QT studies
- 467K+ cardiac sites
- 3M+ patients
- 3,600+ early-phase studies
- 5,400+ late-phase studies
- 136K+ devices shipped annually
Our experience drives a better experience for you
Position your trial for success with our cardiac safety solutions, which provide you with the highest quality patient data on time—and in real time.

Monitor every heartbeat with precision and ensure safety.
To learn more, go to clario.com or email info@clario.com

About Clario
Clario is a global data and technology company that minimizes uncertainty and risk in clinical trials so that customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, Clario balances knowledge of what works with a vision for what’s next, so we can adapt without compromising standards.

Powered by the company’s EXPERT® technology platform, Clario’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. Since 2014, more than half of all FDA drug approvals have come from Clario-supported studies. Pharma companies, biotechs and CROs have relied on Clario solutions in 10,000+ studies, spanning more than three million patients to date. By identifying trial risks before they become problems, Clario enables customers to bring clinical treatments to patients quickly—and with confidence.